Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-01-2007 | Original article

Homocysteine levels are associated with the results of ¹²³I-metaiodobenzylguanidine myocardial scintigraphy in type 2 diabetic patients

Authors: Futoshi Anan, Hidetoshi Yonemochi, Takayuki Masaki, Naohiko Takahashi, Mikiko Nakagawa, Nobuoki Eshima, Tetsunori Saikawa, Hironobu Yoshimatsu

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 1/2007

Abstract

Purpose

Elevated total plasma homocysteine (tHcy) levels and cardiovascular autonomic dysfunction are associated with a high mortality in type 2 diabetic patients. We tested the hypothesis that hyperhomocysteinemia is associated with insulin resistance and cardiovascular autonomic dysfunction in type 2 diabetic patients not receiving insulin treatment.

Methods

The study group consisted of 17 type 2 diabetic patients with high tHcy levels (>15 mmol/l, age 58±5 years, high tHcy group). The control group consisted of 23 age-matched type 2 diabetic patients with normal tHcy levels (≤15 mmol/l, age 58±9 years, normal tHcy group). Cardiovascular autonomic function was assessed by baroreflex sensitivity, heart rate variability, plasma norepinephrine concentrations, and cardiac ¹²³I-metaiodobenzylguanidine (MIBG) scintigraphy.

Results

Early and delayed ¹²³I-MIBG myocardial uptake values were lower (p<0.005 and p<0.01, respectively) and the percent washout rate of ¹²³I-MIBG was higher (p<0.001) in the high tHcy group than in the normal tHcy group. The fasting plasma insulin concentrations (p<0.0001) and the homeostasis model assessment (HOMA) index values (p<0.0001) were higher in the high tHcy group than in the normal tHcy group. Multiple regression analysis revealed that the level of tHcy was independently predicted by the HOMA index values and the myocardial uptake of ¹²³I-MIBG at the delayed phase.

Conclusion

Our results demonstrate that high levels of tHcy are associated with depressed cardiovascular autonomic function and insulin resistance in patients with type 2 diabetes mellitus.

Nygard O, Nordrehaug JE, Refsum H, Ureland PM, farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997;337:230–236PubMedCrossRef

Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. Br Med J 2002;325:1202–1206CrossRef

Tsuji H, Larson MG, Venditti FJ Jr, Manders ES, Evans JC, Feldman CL, et al. Impact of reduced heart rate variability on risk for cardiac events. The Framingham Study. Circulation 1996;94:2850–2855PubMed

La Rovere MT, Bigger JT Jr, Marcus FI, Mortara A, Schwartz PJ. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infraction. ATRAMI (Autonomic Tone and Reflexes After Myocardial Infraction) Investigators. Lancet 1998;351:478–484PubMedCrossRef

Reichard P, Pihl M. Mortality and treatment side-effects during long-term intensified conventional insulin treatment in the Stockholm Diabetes Intervention Study. Diabetes 1994;43:313–317PubMedCrossRef

Takahashi N, Nakagawa M, Saikawa T, Ooie T, Yufu K, Shigematsu S, et al. Effect of essential hypertension on cardiac autonomic function in type 2 diabetic patients. J Am Coll Cardiol 2001;38:232–237PubMedCrossRef

Takahashi N, Anan F, Nakagawa M, Yufu K, Ooie T, Nawata T, et al. Microalbuminuria, cardiovascular autonomic dysfunction, and insulin resistance in patients with type 2 diabetes mellitus. Metabolism 2004;53:1359–1364PubMedCrossRef

Anan F, Takahashi N, Ooie T, Nakagawa M, Saikawa T, Yoshimatsu H. High-sensitivity C-reactive protein is associated with insulin resistance and cardiovascular autonomic dysfunction in type 2 diabetic patients. Metabolism 2005;54:552–558PubMedCrossRef

Giltay EJ, Hoogeveen EK, Elbers JM, Gooren LJ, Asscheman H, Stehouwer CD. Insulin resistance is associated with elevated plasma homocysteine levels in healthy, non-obese subjects. Arteriosclerosis 1998;139:197–198CrossRef

10.

Emoto M, Kanda H, Shoji T, Kawagishi T, Komatsu M, Mori K, et al. Impact of insulin resistance and nephropathy on homocysteine in type 2 diabetes. Diabetes Care 2001;24:533–538PubMedCrossRef

11.

Gerritsen J, TenVoorde BJ, Dekker JM, Kingma R, Kostense PJ, Bouter LM, et al. Measures of cardiovascular autonomic dysfunction nervous function: agreement, reproducibility, and reference values in middle age and elderly subjects. Diabetologia 2003;46:330–338PubMed

12.

Sakata K, Shirotani M, Yoshida H, Kurata C. Cardiac sympathetic nervous system in early essential hypertension assessed by ¹²³I-MIBG. J Nucl Med 1999;40:6–11PubMed

13.

Spallone V, Menzinger G. Diagnosis of cardiovascular autonomic neuropathy in diabetes. Diabetes 1997;46:S67–S76PubMed

14.

Watanabe K, Sekiya M, Tsuruoka T, Funada J, Kameoka H, Miyagawa M, et al. Relationship between insulin resisatnce and cardiac sympathetic nervous function in essential hypertension. J Hypertens 1999;17:1161–1168PubMedCrossRef

15.

Liao D, Sloan RP, Cascio WE, Folsom AR, Liese AD, Evans GW, et al. Multiple metabolic syndrome is associated with lower heart rate variability. The Atherosclerosis Risk in Communities Study. Diabetes Care 1998;21:2116–2122PubMedCrossRef

16.

Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412–419PubMedCrossRef

17.

Donnelly JG, Pronovost C. Evaluation of the Abbott IMx fluorescence polarization immunoassay and the Bio-Rad enzyme immunoassay for homocysteine: comparison with high-performance liquid chromatography. Ann Clin Biochem 2000;37:194–198PubMedCrossRef

18.

Davies L, Wilmshurst EG, McElduff A, Gunton J, Clifton-Bligh P, Fulcher GR. The relationship among homocysteine, creatinine clearance, and albuminuria in patients with type 2 diabetes. Diabetes Care 2001;24:1805–1809PubMedCrossRef

19.

Sato T, Nishinaga M, Kawamoto A, Ozawa T, Takatsuji H. Accuracy of a continuous blood pressure monitor based on arterial tonometry. Hypertension 1993;21:866–874PubMed

20.

Loscalzo J. The oxidant stress of hyperhomocyst(e)inemia. J Clin Invest 1996;98:5–7PubMedCrossRef

21.

Tirosh A, Potashnik R, Bashan N, Rudich A. Oxidant stress disrupts insulin-induced redistribution of insulin receptor substrate-1 and phosphatidylinositol 3-kinase in 3T3-L1 adipocytes. A putative cellular mechanism for impaired protein kinase B activation and glut4 translocation. J Biol Chem 1999;274:10595–10602PubMedCrossRef

22.

Najib S, Sanchez-Margalet V. Homocysteine thiolactone inhibits insulin signaling and glutathione has a protective effects. J Mol Endocrinol 2001;27:85–91PubMedCrossRef

23.

Jacobs RL, House JD, Brosnan ME, Brosnan JT. Effects of treptozotocin-induced diabetes and insulin treatment on homocysteine metabolism rat. Diabetes 1998;47:1967–1970PubMedCrossRef

24.

Fonseca V, Dicker-Brown A, Ranganathan S, Song W, Barnard RJ, Fink L, et al. Effects of a high-fat-sucrose diet on enzymes in homocysteine metabolism in the rat. Metabolism 2000;49:736–741PubMedCrossRef

25.

Ambrosch A, Dierkes J, Lobmann R, Kuhne W, Konig W, Luley C, et al. Relation between homocysteinaemia and diabetic neuropathy in patients with type 2 diabetes mellitus. Diabetic Med 2001;174:185–192CrossRef

26.

Cohen JA, Jeffers BW, Stabler S, Schrier RW, Estascio R. Increasing homocysteine levels and diabetic autonomic neuropathy. Auton Neurosci 2001;87:268–273PubMedCrossRef

27.

Spoelstra-De Man AM, Smulders YM, Dekker JM, Heine RJ, Bouter LM, Nijpels G, et al. Homocysteine levels are not associated with cardiovascular autonomic function in elderly Caucasian subjects without or with type 2 diabetes mellitus: Hoorn study. J Intern Med 2005;258:536–543PubMedCrossRef

28.

Mantysaari M, Kuikka J, Mustonen J, Tahvanainen K, Vanninen E, Lansimies E, et al. Noninvasive detection of cardiac sympathetic nervous dysfunction in diabetic patients using [¹²³I] metaiodobenzylguanidine. Diabetes 1992;41:1069–1075PubMedCrossRef

29.

Schnell O, Muhr D, Weiss M, Kirsch CM, Haslbeck M, Tatsch K, et al. Three-year follow-up on scintigraphically assessed cardiac sympathetic denervation in patients with long-term insulin-dependent (type I) diabetes mellitus. J Diabetes Complicat 1997;11:307–313PubMedCrossRef

30.

Weir DG, Scott JM. The biochemical basis of neuropathy in cobalamin deficiency. Bailliere’s Clin Heamatol 1995;8:479–497CrossRef

31.

Chowdhary S, Vaile JC, Fletcher J, Ross HF, Coote JH, Townend JN. Nitric oxide and cardiac autonomic control in humans. Hypertension 2000;36:264–269PubMed

32.

Davis JI, Band M, Morris A, Struthers AD. Spironolactone impaires endothelial dysfunction and heart rate variability in patients with type 2 diabetic. Diabetologia 2004;47:1687–1694CrossRef

33.

Meigs J, Jacques P, Selhub J, Singer D, Nathan D, Rifai N, et al. Fasting plasma homocysteine levels in the insulin resistance syndrome. The Framingham Offspring study. Diabetes Care 2001;24:1403–1410PubMedCrossRef

34.

Wheeler DC, Townend JN, Landray MJ. Cardiovascular risk factors in predialysis patients: baseline data from the Chronic Renal Impairment in Birmingham (CRIB) study. Kidney Int Suppl 2003;84:S201–S203PubMedCrossRef

35.

Bostom AG, Shemin D, Verhoef P, Nadeau MR, Jacques PF, Selhub J, et al. Elevated fasting total plasma homocyateine levels and cardiovascular disease outcomes in maintenance dialysis patients: a prospective study. Arterioscler Thromb Vasc Biol 1997;17:2554–2558PubMed

36.

Davies L, Wilmshurst EG, Mcelduff A, Gunton J, Clifton-Bligh P, Fulcher GR. The relationship among homocysteine, creatinine clearance, and albuminuria in patients with type 2 diabetes. Diabetes Care 2001;24:1805–1809PubMedCrossRef

37.

Gavras HP. Issues in hypertension: drug tolerability and special populations. Am J Hypertens 2001;14(Pt 2):231S–236SPubMedCrossRef

38.

Lender D, Arauz-Pacheco C, Breen L, Mora-Mora P, Ramirez LC, Raskin P. A double blind comparison of the effects of amlodipine and enalapril on insulin sensitivity in hypertensive patients. Am J Hypertens 1999;12:298–303PubMedCrossRef

39.

Kontopoulos AG, Athyros VG, Didangelos TP, Papageorgiou AA, Avramidis MJ, Mayroudi MC, et al. Effect of chronic quinapril administration on heart rate variability in patients with diabetic autonomic neuropathy. Diabetes Care 1997;20:355–361PubMedCrossRef

40.

Rodgers JE, Patterson JH. Angiotensin II-receptor blockers: clinical relevance and therapeutic role. Am J Health Syst Pharm 2001;58:671–683PubMed

41.

Lefrandt JD, Heitmann J, Sevre K, Castelloano M, Hausberg M, Fallon M, et al. The effects of dihydropyridine and phenylalkylamine calcium antagonist classes on autonomic function in hypertension: the VAMPHYRE study. Am J Hypertens 2001;14:1083–1089PubMedCrossRef

42.

Yamashina S, Yamazaki J. Role of MIBG myocardial scintigraphy in the assessment of heart failure: the need to establish evidence. Eur J Nucl Med Mol Imaging 2004;31:1353–1355PubMedCrossRef

43.

Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, et al. Effects of candesartan on cardiac sympathetic nerve activity in patients with congestive heart faiure and preserved left ventricular ejection fraction. J Am Coll Cardiol 2005;45:661–667PubMedCrossRef

Title: Homocysteine levels are associated with the results of 123I-metaiodobenzylguanidine myocardial scintigraphy in type 2 diabetic patients
Authors: Futoshi Anan
Hidetoshi Yonemochi
Takayuki Masaki
Naohiko Takahashi
Mikiko Nakagawa
Nobuoki Eshima
Tetsunori Saikawa
Hironobu Yoshimatsu
Publication date: 01-01-2007
Publisher: Springer-Verlag
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 1/2007
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-006-0200-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Homocysteine levels are associated with the results of ¹²³I-metaiodobenzylguanidine myocardial scintigraphy in type 2 diabetic patients

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2007

Detection of 99mTc-sestamibi uptake in brown adipose tissue with SPECT-CT

Reproducibility of [123I]PE2I binding to dopamine transporters with SPECT

Diagnostic value of kinetic analysis using dynamic FDG PET in immunocompetent patients with primary CNS lymphoma

Can the detection of misery perfusion in chronic cerebrovascular disease be based on reductions in baseline CBF and vasoreactivity?

99mTc-ECD brain perfusion SPECT in hyperalgesic fibromyalgia

Bone involvement in patients with lymphoma: the role of FDG-PET/CT